|Articles|June 22, 2017
PAREXEL is Acquired by Pamplona Capital Management
Advertisement
PAREXEL International Corporation announced that Pamplona Capital Management, LLP has acquired all of its outstanding shares, including Parexel's net debt, for $88.10 per share in cash-valued at approximately $5 billion.
Read the full release
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Agentic AI and the Administrative Backbone of Clinical Trials: Why the Operating Model Has to Change First
2
Introducing The Human Side of Clinical Trials
3
AI Moves Patient Recruitment from Trial Bottleneck to Competitive Edge: A 2026 Perspective
4
Why Quantifying the Financial Value of RBQM Has Been So Hard—and What This Study Did Differently
5